Zdravljenje pridobljene hemofilije. Irena Preložnik Zupan

Similar documents
Introduction to coagulation and laboratory tests

Review of the TICH-2 Trial

True/False: Idarucizumab can be utilized for the management of bleeding associated with dabigatran.

Discuss the role of idarucizumab for the management of bleeding associated with dabigatran

Prothrombin Complex Concentrate- Octaplex. Octaplex

Primary Exam Physiology lecture 5. Haemostasis

3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?

Chapter 1 Introduction

Recombinant Factor VIIa for Intracerebral Hemorrhage

WHITE PAPERS PRESENTATION VIDEO DOCUMENTATION EXPERIMENT WO NDCLOT. The WoundClot Principals for Effective Bleeding Control PRESENTATION

Blood coagulation and fibrinolysis. Blood clotting (HAP unit 5 th )

Inherited Thrombophilia Testing. George Rodgers, MD, PhD Kristi Smock MD

Profilaktično zdravljenje hemofilije. Simpozij Bayer Maj 2011

Recombinant factor VIIa: Hype or hope? Jed Gorlin MD, MBA

Blood clotting. Subsequent covalent cross-linking of fibrin by a transglutaminase (factor XIII) further stabilizes the thrombus.

Priporočila za zdravljenje primarne imunske trombocitopenije. Barbara Skopec

Bleeding and Haemostasis. Saman W.Boskani HDD, FIBMS Maxillofacial Surgeon

Antithrombotic therapy in the ACS patient with atrial fibrillation

Approach to bleeding disorders &treatment. by RAJESH.N General medicine post graduate

Anticoagulants: Agents, Pharmacology and Reversal

Hemlibra (emicizumab-kxwh) NEW PRODUCT SLIDESHOW

Hemostasis and Thrombosis for Primary Care Providers: An Update. Andrew D. Leavitt, MD. May 21, Topic Outline. Direct Oral Anti-Coagulants DOACs

Part IV Antithrombotics, Anticoagulants and Fibrinolytics

Ch. 45 Blood Plasma proteins, Coagulation and Fibrinolysis Student Learning Outcomes: Describe basic components of plasma

Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants

THROMBOTIC DISORDERS: The Final Frontier

Emergency Management of Patients on Direct Oral Anticoagulants (DOACs)

Coagulopathy Case - 3. Andy Nguyen, M.D. 2009

Acquired Inhibitors of Coagulation

Platelet-fibrin clot. 50Kd STEMI. Abciximab. Video of a IIb/IIIa inhibitor in action. Unstable Angina and non-stsegment

Hemostasis. Learning objectives Dr. Mária Dux. Components: blood vessel wall thrombocytes (platelets) plasma proteins

Emergency Blood and Massive Transfusion: The Surgeon s Perspective. Transfusion Medicine Update September 16 17, 2009

Insights on the Quality of Coagulation Testing

Clinical issues which drug for which patient

An Overview of Non Vitamin-K Antagonist Oral Anticoagulants. Helen Williams Consultant Pharmacist for CV Disease South London

Recombinant Activated Factor VII: Useful. Department of Surgery Grand Rounds 11/8/10 David Mauchley MD

David Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy

Update with the New Oral Anticoagulants: Today s Issues for the Front Line Pharmacist

New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY

Antithrombotic Efficacy and Safety of Dabigatran Etexilate

Hemostasis. Clo)ng factors and Coagula4on NORMAL COAGULATION. Overview of blood coagula4on. The Cascade Theory 5/1/12. Clot

New drugs for anticoagulation so much choice, how do they compare? Dr Patrick Kesteven Newcastle

ACQUIRED COAGULATION ABNORMALITIES

Approach to bleeding

Factor VIIa-Antithrombin complex levels and Factor Xa generation in CAD patients

Bleeding Disorders. Dr. Mazen Fawzi Done by Saja M. Al-Neaumy Noor A Mohammad Noor A Joseph Joseph

New Clinical Results with Fitusiran

New Oral Anticoagulant Drugs in the Prevention of DVT

Dr Tina Biss Consultant Haematologist Newcastle Hospitals NHS Foundation Trust. North East RTC Annual Education Symposium 16 th October 2014

3/25/2016. Objectives for Pharmacists. Stop the Bleeding! New Reversal Agents. Objectives for Pharmacy Technicians. Assessment Pre-test

Important Considera/ons for Coagula/on Tests on Children and Neonates

Supplementary Appendix

Update on Antithrombotic Therapy in Acute Coronary Syndrome

Diagnosis of hypercoagulability is by. Molecular markers

Targeting a Network Anticoagulation Issue. Anthony J. Macchiavelli, M.D., FHM

심방세동과최신항응고요법 RACE II AFFIRM 항응고치료는왜중요한가? Rhythm control. Rate control. Anticoagulation 남기병 서울아산병원내과. Clinical Impact of Atrial Fibrillation

Reversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016

4/23/2009. September 15, 2008

Disseminated Intravascular Coagulation. M.Bahmanpour MD Assistant professor IUMS

Prevention of bleeding in surgical interventions or invasive procedures in congenital FVII deficiency (1.4)

Biochemical Reaction Networks and Blood Clotting

Anticoagulation Beyond Coumadin

FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS

Reversal of Anticoagulants at UCDMC

Agent Dose MoA/PK/Admin Adverse events Disadvantages Protamine Heparin: 1mg neutralizes ~ 100 units Heparin neutralization in ~ 5 min

Practical issues with NOACs «The Grey Zones»

Recombinant Activated Factor VII in Controlling Bleeding in Non-Hemophiliac Patients

This slide belongs to iron lecture and it is to clarify the iron cycle in the body and the effect of hypoxia on erythropoitein secretion

96 Current Management of Hemophilia

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CORE SPC FOR HUMAN PROTHROMBIN COMPLEX PRODUCTS (CPMP/BPWG/3735/02)

Coagulation an Overview Dr.Abdolreza Abdolr Afrasiabi Thal assem a & Heamophili hilia G ene i tic R esearc C en er Shiraz Medical Medic University

Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF

APPENDIX 2 Eight New Cases of LAHS and Review of Literature: Treatment and Follow-Up

DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center

VENOUS THROMBOEMBOLISM PHARMACOLOGY. University of Hawai i Hilo DNP Program NURS 603 Advanced Clinical Pharmacology Danita Narciso Pharm D

New Age Anticoagulants: Bleeding Considerations

L iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche

Cigna Drug and Biologic Coverage Policy

Topics of today lectures: Hemostasis

NovoSeven RT Coagulation Factor VIIa (Recombinant) Room Temperature Stable, Lyophilized Powder For Intravenous Use Only Initial U.S.

Local vasoconstriction. is due to local spasm of the smooth muscle (symp. reflex) can be maintained by platelet vasoconstrictors

New oral anticoagulants and Palliative Care.

General approach to the investigation of haemostasis. Jan Gert Nel Dept. of Haematology University of Pretoria 2013

Which drug do you prefer for stable CAD? - P2Y12 inhibitor

Hemodynamics. Objectives. Filtration across the endothelium 1/17/2017. K[(P cap - P int )-σ(π cap π int )]

Thromboembolic Adverse Events After Use of Recombinant Human Coagulation Factor VIIa

Will Oral Anticoagulants Continue to Evolve?

A Bruising Loss. Clinical Problem-Solving

PRODUCT MONOGRAPH. eptacog alfa (activated) Activated Recombinant Human Blood Coagulation Factor VII Room Temperature Stable

Internal Quality Control in the Haemostasis laboratory. Dr Steve Kitchen Sheffield Haemophilia and Thrombosis centre & UK NEQAS Blood Coagulation

Warfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin

NOVO NORDISK A/S. 250 KIU/vial), 1 mg/ml after reconstitution

Treating breakthrough bleeds: A new approach

Anticoagulants. Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT

Cancer Associated Thrombosis An update.

Direct Oral Anticoagulants An Update

Old and New Anticoagulants For Stroke Prevention Benefits and Risks

Recurrent life-threatening bleeding due to acquired clotting factor XIII inhibitor in a Chinese patient with systemic lupus erythematosus

Joost van Veen Consultant Haematologist

fritsmafactor.com Coag QA: Why are we Different? Prothrombin Time 1980: PT Ratio Based on MRI PTR = PTpatient PTMRI

Transcription:

Zdravljenje pridobljene hemofilije Irena Preložnik Zupan

CILJI 1. Definicija, klinična slika, diagnoza 2. Zdravljenje zdravljenje akutnih krvavitev odstranjevanje inhibitorjev

Pridobljeni inhibitorji koagulacije PROTITELESA, KI NEVTRALIZIRAJO FUNKCIJO ALI ODSTRANIJO KOAGULACIJSKE FAKTORJE IZ OBTOKA

Vrste inhibitorjev Aloprotitelesa pojavijo se pri bolnikih s podedovano hemofilijo Autoprotitelesa nastanejo de novo pri bolnikih brez znanega pomanjkanja koagulacijskih F Z drugimi autoimunskimi obolenji Z limfoproliferativnimi obolenji - KLL Starost - bifazično

Komorbidnostna stanja Nosečnost Avtoimunske bolezni (SLE, RA, MS, SS, AIHA..) Solidni tumorji (prostata, pljuča, kolon ) Hematološke bolezni (KLL, NHL, DP, LPI, MDS) Vnetna črevesna bolezen Dermatološke bolezni Sladkorna bolezen Hepatitis B, C Zdravila (penicilini, interferon, fludarabin)

Intrinzična pot XIIa Ekstrinzična pot XIa TF Prothrombin IXa VIII VIIIa VIIa Xa Va V Soft clot Thrombin Fibrinogen Fibrin XIIIa Hard clot Fibrin

Incidenca inhibitorjev VSA AUTOPROTITELESA SO REDKA! Most frequent Factor VIII, VWF, Factor II (APS?) Less common Factor V, IX, XI, XIII Rare but reported Fibrinogen, VII, X

Klinična slika pridobljene hemofilije Obsežne krvavitve najpogosteje sluznične, mišični hematomi, GI krvavitve, hematurija Jatrogeno - IV lines, bladder catheterization or post surgical bleeding 80-90% obsežne krvavitve ob ugotovitvi 10-22% smrtnost

Klasična hemofilija Klinična slika Krvavitve v kožo, mišice, mehka tkiva, sluznice (epistakse, GIT in urološke krvavitve, retroperitonealne krvavitve, popororne krvavitve)

Left-hand hematoma developed 3 days after surgical incision of the right-hand hematoma, which was initially misdiagnosed as cellulitis

Diagnoza pridobljene hemofilije Klinična slika Nenaden pojav obsežnih hematomov PČ in PTČ sta presejalna testa Normalen PČ Podaljšan PTČ DD-pomanjk F XI,IX,VIII, vwd, inhibitorji, heparin, AFS

Diagnoza pridobljene hemofilije PATIENT BLOOD: NORMAL BLOOD: FACTOR LEVEL 0% aptt 80 sec FACTOR LEVEL 100% aptt 28 sec MIXING STUDY NOTE: ONLY 30-40% FACTOR REQUIRED FOR NORMAL aptt 50% PATIENT : 50% NORMAL RESULT A No correction INHIBITOR FACTOR LEVEL 20% aptt 50 sec RESULT B FACTOR LEVEL 50% aptt 30 sec Correction FACTOR DEFICIENCY

Zdravljenje pridobljene hemofilije Zdravljenje aktivne krvavitve Odločitev je odvisna od resnosti krvavitve in titra protiteles Odstranjevanje inhibitorjev Imunosupresivno zdravljenje Imunoglobulini Plazmafereze Imunska toleranca Rituximab

Zdravljenje aktivne krvavitve Koncentrat F VIII (če < 5 BE) Visoki odmerki kot hemofilija z inhibitorji Bypassing agents r FVIIa (90 µg/kg q 2-6 h) (94% effective) (običajni odmerki 90-200 µg/kg na 2-6 hrs-not studied) FEIBA (70 U/kg na 8-12 h) (81% effective)

Kako učinkovit je rfviia pri pridobljeni hemofiliji?

Compassionate Use: Acquired Inhibitors Učinkovitost rfviia 38 bolnikov, 60 krvavitev 100 90 80 70 Bleeding episodes (%) 60 50 40 30 20 10 0 100% Good Partial Poor 75% 17% 8% Salvage 1st Line 92% good/partial response rate with salvage therapy 100% excellent/good response rate with first-line therapy Hay CRM, et al. Thromb Haemost. 1997;79:1463-1467.

Stranski učinki zdravljenja krvavitev r FVIIa - Tromboze (< 2%?) FEIBA Tromboze Alergične reakcije Low risk for transmission of infectious agents

Arterial and Fatal Thromboembolic SAEs Data from ICH Study Arterial thromboembolic SAEs occurred significantly (P = 0.01) more frequently with rfviia treatment (5%) than with placebo (0%) These events manifested in the form of myocardial ischemic events (7) and cerebral infarction (9) Thromboembolic SAEs that were fatal or disabling occurred in 2% of rfviia-treated patients compared with 2% in the placebo group Mayer SA et al. N Engl J Med. 2005;352:777-785. 399 bolnikov-cvi

Odstranjevanje inhibitorjev IMUNOSUPRESIVNO ZDRAVLJENJE Prednizolon zdravilo prvega reda 1mg/kg/dan 3-6 tednov Ciklofosfamid 1-2mg/kg/dan dodati prednizolonu takoj ali po 3 tednih Drugi: Cyclosporine, tacrolimus, azathioprine, mycophenolate mofetil

Odstranjevanje inhibitorjev IMUNOGLOBULINI veliki odmerki 2g/kg 2dni ali 0,4g/kg 5dni Sedanji rezultati kliničnih študij kažejo, da niso uporabni v prvi liniji ali kot samostojno zdravilo Lahko jih dodamo: Steroidom Plazmaferezi Imuski toleranci

Odstranjevanje inhibitorjev PLAZMAFEREZE začasna, hitra odstranitev protiteles, še posebej v primeru hudih krvavitev pri visokem titru inhibitorjev

Odstranjevanje inhibitorjev IMUNSKA TOLERANCA - študije Podobno kot pri podedovani hemofiliji Za rezistentne bolnike Modificiran Bonn-Malmo protokol Ciklofosfamid 1-2mg/kg/dan Prednizolon 1mg/kg/dan Plazmafereze 2-3V plazme (1-5dan/teden) Imunoglobulini 0.3g/kg (5-7dan/teden) FVIII koncentrat 100IU/kg/dan

Kaj pa Rituximab?

Odstranjevanje inhibitorjev RITUXIMAB malo izkušenj (29 objav) 375mg/m2 4 tedne zapored + imunosupresiv prednizolon, ciklofosfamid Dovoljeno kot zdravilo drugega reda Nekateri avtorji priporočajo prva linija pri bolnikih z visokim titrom protiteles Če se bolezen ponovi- ponoviti zdravljenje